Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy

PCT No. PCT/JP93/01250 Sec. 371 Date Apr. 7, 1994 Sec. 102(e) Date Apr. 7, 1994 PCT Filed Sep. 3, 1993 PCT Pub. No. WO94/05299 PCT Pub. Date Mar. 17, 1994.A pharmaceutical composition for use as a nephrotoxicity alleviator for alleviating the nephrotoxicity caused by a drug administered into the liv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KAWABATA, HIRONORI, ENDO, TAKESHI, MORIGUCHI, KOEI
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	KAWABATA HIRONORI ENDO TAKESHI MORIGUCHI KOEI
description	PCT No. PCT/JP93/01250 Sec. 371 Date Apr. 7, 1994 Sec. 102(e) Date Apr. 7, 1994 PCT Filed Sep. 3, 1993 PCT Pub. No. WO94/05299 PCT Pub. Date Mar. 17, 1994.A pharmaceutical composition for use as a nephrotoxicity alleviator for alleviating the nephrotoxicity caused by a drug administered into the living organism, which composition contains S-adenosyl-L-methionine or a salt thereof as an active ingredient is provided. Also provided is a pharmaceutical composition for use as an agent for potentiating the antitumor activity of platinum complex compounds, which composition contains S-adenosyl-L-methionine as an active ingredient.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US5466678A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US5466678A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US5466678A3</originalsourceid><addsrcrecordid>eNqFjD0KAjEQhbexEPUM5gKp1Ggri2Jht9q6hOwsGcjOhGQEc3uzYG_1Ht_7WTavlrUdJiTMkqwgk-JRdZUBcS5B3_UE4itHAiWsEgxvV50HRRB9YuEPOpQy7xzmGOoLzXmysaybxWhDhs1PV832enm0Nw2Re8jROiCQ_tkd9saY4-m8-9_4AnRMPHA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy</title><source>esp@cenet</source><creator>KAWABATA; HIRONORI ; ENDO; TAKESHI ; MORIGUCHI; KOEI</creator><creatorcontrib>KAWABATA; HIRONORI ; ENDO; TAKESHI ; MORIGUCHI; KOEI</creatorcontrib><description>PCT No. PCT/JP93/01250 Sec. 371 Date Apr. 7, 1994 Sec. 102(e) Date Apr. 7, 1994 PCT Filed Sep. 3, 1993 PCT Pub. No. WO94/05299 PCT Pub. Date Mar. 17, 1994.A pharmaceutical composition for use as a nephrotoxicity alleviator for alleviating the nephrotoxicity caused by a drug administered into the living organism, which composition contains S-adenosyl-L-methionine or a salt thereof as an active ingredient is provided. Also provided is a pharmaceutical composition for use as an agent for potentiating the antitumor activity of platinum complex compounds, which composition contains S-adenosyl-L-methionine as an active ingredient.</description><edition>6</edition><language>eng</language><subject>CHEMISTRY ; DERIVATIVES THEREOF ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SUGARS</subject><creationdate>1995</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19951114&DB=EPODOC&CC=US&NR=5466678A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19951114&DB=EPODOC&CC=US&NR=5466678A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KAWABATA; HIRONORI</creatorcontrib><creatorcontrib>ENDO; TAKESHI</creatorcontrib><creatorcontrib>MORIGUCHI; KOEI</creatorcontrib><title>Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy</title><description>PCT No. PCT/JP93/01250 Sec. 371 Date Apr. 7, 1994 Sec. 102(e) Date Apr. 7, 1994 PCT Filed Sep. 3, 1993 PCT Pub. No. WO94/05299 PCT Pub. Date Mar. 17, 1994.A pharmaceutical composition for use as a nephrotoxicity alleviator for alleviating the nephrotoxicity caused by a drug administered into the living organism, which composition contains S-adenosyl-L-methionine or a salt thereof as an active ingredient is provided. Also provided is a pharmaceutical composition for use as an agent for potentiating the antitumor activity of platinum complex compounds, which composition contains S-adenosyl-L-methionine as an active ingredient.</description><subject>CHEMISTRY</subject><subject>DERIVATIVES THEREOF</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SUGARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1995</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjD0KAjEQhbexEPUM5gKp1Ggri2Jht9q6hOwsGcjOhGQEc3uzYG_1Ht_7WTavlrUdJiTMkqwgk-JRdZUBcS5B3_UE4itHAiWsEgxvV50HRRB9YuEPOpQy7xzmGOoLzXmysaybxWhDhs1PV832enm0Nw2Re8jROiCQ_tkd9saY4-m8-9_4AnRMPHA</recordid><startdate>19951114</startdate><enddate>19951114</enddate><creator>KAWABATA; HIRONORI</creator><creator>ENDO; TAKESHI</creator><creator>MORIGUCHI; KOEI</creator><scope>EVB</scope></search><sort><creationdate>19951114</creationdate><title>Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy</title><author>KAWABATA; HIRONORI ; ENDO; TAKESHI ; MORIGUCHI; KOEI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US5466678A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1995</creationdate><topic>CHEMISTRY</topic><topic>DERIVATIVES THEREOF</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SUGARS</topic><toplevel>online_resources</toplevel><creatorcontrib>KAWABATA; HIRONORI</creatorcontrib><creatorcontrib>ENDO; TAKESHI</creatorcontrib><creatorcontrib>MORIGUCHI; KOEI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KAWABATA; HIRONORI</au><au>ENDO; TAKESHI</au><au>MORIGUCHI; KOEI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy</title><date>1995-11-14</date><risdate>1995</risdate><abstract>PCT No. PCT/JP93/01250 Sec. 371 Date Apr. 7, 1994 Sec. 102(e) Date Apr. 7, 1994 PCT Filed Sep. 3, 1993 PCT Pub. No. WO94/05299 PCT Pub. Date Mar. 17, 1994.A pharmaceutical composition for use as a nephrotoxicity alleviator for alleviating the nephrotoxicity caused by a drug administered into the living organism, which composition contains S-adenosyl-L-methionine or a salt thereof as an active ingredient is provided. Also provided is a pharmaceutical composition for use as an agent for potentiating the antitumor activity of platinum complex compounds, which composition contains S-adenosyl-L-methionine as an active ingredient.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US5466678A
source	esp@cenet
subjects	CHEMISTRY DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS
title	Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T09%3A29%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KAWABATA;%20HIRONORI&rft.date=1995-11-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS5466678A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true